Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 206

1.

CCR5AS lncRNA variation differentially regulates CCR5, influencing HIV disease outcome.

Kulkarni S, Lied A, Kulkarni V, Rucevic M, Martin MP, Walker-Sperling V, Anderson SK, Ewy R, Singh S, Nguyen H, McLaren PJ, Viard M, Naranbhai V, Zou C, Lin Z, Gatanaga H, Oka S, Takiguchi M, Thio CL, Margolick J, Kirk GD, Goedert JJ, Hoots WK, Deeks SG, Haas DW, Michael N, Walker B, Le Gall S, Chowdhury FZ, Yu XG, Carrington M.

Nat Immunol. 2019 Jul;20(7):824-834. doi: 10.1038/s41590-019-0406-1. Epub 2019 Jun 17.

PMID:
31209403
2.

GCH1 haplotypes and cardiovascular risk in HIV.

Slaven JE, Haas DW, Liu Z, Stein JH, Brown TT, Gupta SK.

AIDS. 2019 Aug 1;33(10):1669-1671. doi: 10.1097/QAD.0000000000002263.

PMID:
31082861
3.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.

Desta Z, Gammal RS, Gong L, Whirl-Carrillo M, Gaur AH, Sukasem C, Hockings J, Myers A, Swart M, Tyndale RF, Masimirembwa C, Iwuchukwu OF, Chirwa S, Lennox J, Gaedigk A, Klein TE, Haas DW.

Clin Pharmacol Ther. 2019 Oct;106(4):726-733. doi: 10.1002/cpt.1477. Epub 2019 Jul 5.

PMID:
31006110
4.

Influence of tissue context on gene prioritization for predicted transcriptome-wide association studies.

Li B, Veturi Y, Bradford Y, Verma SS, Verma A, Lucas AM, Haas DW, Ritchie MD.

Pac Symp Biocomput. 2019;24:296-307.

5.

Dolutegravir plus lamivudine for initial treatment of HIV-1-infected participants with HIV-1 RNA <500 000 copies/mL: week 48 outcomes from ACTG 5353.

Nyaku AN, Zheng L, Gulick RM, Olefsky M, Berzins B, Wallis CL, Godfrey C, Sax PE, Acosta EP, Haas DW, Smith KY, Sha BE, Van Dam CN, Taiwo BO; ACTG A5353 Study Team .

J Antimicrob Chemother. 2019 May 1;74(5):1376-1380. doi: 10.1093/jac/dky564.

PMID:
30668695
6.

Pharmacogenetics and pharmacokinetics of CNS penetration of efavirenz and its metabolites.

Decloedt EH, Sinxadi PZ, van Zyl GU, Wiesner L, Khoo S, Joska JA, Haas DW, Maartens G.

J Antimicrob Chemother. 2019 Mar 1;74(3):699-709. doi: 10.1093/jac/dky481.

PMID:
30535366
7.

Building capacity for advances in tuberculosis research; proceedings of the third RePORT international meeting.

van der Heijden YF, Abdullah F, Andrade BB, Andrews JR, Christopher DJ, Croda J, Ewing H, Haas DW, Hatherill M, Horsburgh CR Jr, Mave V, Nakaya HI, Rolla V, Srinivasan S, Sugiyono RI, Ugarte-Gil C, Hamilton C.

Tuberculosis (Edinb). 2018 Dec;113:153-162. doi: 10.1016/j.tube.2018.09.009. Epub 2018 Oct 1.

PMID:
30514497
8.

Precision HIV care: responding to old questions and meeting new challenges.

Hulgan T, Dash C, Haas DW, Phillips EJ.

Pharmacogenomics. 2018 Nov;19(17):1299-1302. doi: 10.2217/pgs-2018-0126. Epub 2018 Oct 16. No abstract available.

9.

Antiretroviral Concentrations in Hair Strongly Predict Virologic Response in a Large Human Immunodeficiency Virus Treatment-naive Clinical Trial.

Gandhi M, Bacchetti P, Ofokotun I, Jin C, Ribaudo HJ, Haas DW, Sheth AN, Horng H, Phung N, Kuncze K, Okochi H, Landovitz RJ, Lennox J, Currier JS; AIDS Clinical Trials Group (ACTG) 5257 Study Team.

Clin Infect Dis. 2019 Mar 5;68(6):1044-1047. doi: 10.1093/cid/ciy764.

10.

Hemochromatosis (HFE) Gene Variants Are Associated with Increased Mitochondrial DNA Levels During HIV-1 Infection and Antiretroviral Therapy.

Kallianpur AR, Gerschenson M, Hulgan T, Kaur H, Clifford DB, Haas DW, Murdock DG, McArthur JC, Samuels DC, Simpson DM.

AIDS Res Hum Retroviruses. 2018 Nov;34(11):942-949. doi: 10.1089/AID.2018.0025. Epub 2018 Aug 22.

PMID:
29968489
11.

Drug metabolism and transport gene polymorphisms and efavirenz adverse effects in Brazilian HIV-positive individuals.

de Almeida TB, de Azevedo MCVM, Pinto JFDC, Ferry FRA, da Silva GAR, de Castro IJ, Baker P, Tanuri A, Haas DW, Cardoso CC.

J Antimicrob Chemother. 2018 Sep 1;73(9):2460-2467. doi: 10.1093/jac/dky190.

12.

Brain neurotransmitter transporter/receptor genomics and efavirenz central nervous system adverse events.

Haas DW, Bradford Y, Verma A, Verma SS, Eron JJ, Gulick RM, Riddler SA, Sax PE, Daar ES, Morse GD, Acosta EP, Ritchie MD.

Pharmacogenet Genomics. 2018 Jul;28(7):179-187. doi: 10.1097/FPC.0000000000000341.

13.

Killer cell immunoglobulin-like receptor 3DL1 variation modifies HLA-B*57 protection against HIV-1.

Martin MP, Naranbhai V, Shea PR, Qi Y, Ramsuran V, Vince N, Gao X, Thomas R, Brumme ZL, Carlson JM, Wolinsky SM, Goedert JJ, Walker BD, Segal FP, Deeks SG, Haas DW, Migueles SA, Connors M, Michael N, Fellay J, Gostick E, Llewellyn-Lacey S, Price DA, Lafont BA, Pymm P, Saunders PM, Widjaja J, Wong SC, Vivian JP, Rossjohn J, Brooks AG, Carrington M.

J Clin Invest. 2018 May 1;128(5):1903-1912. doi: 10.1172/JCI98463. Epub 2018 Apr 3.

14.

Development and validation of an assay to analyze atazanavir in human hair via liquid chromatography/tandem mass spectrometry.

Phung N, Kuncze K, Okochi H, Louie A, Benet LZ, Ofokotun I, Haas DW, Currier JS, Chawana TD, Sheth AN, Bacchetti P, Gandhi M, Horng H.

Rapid Commun Mass Spectrom. 2018 Mar 15;32(5):431-441. doi: 10.1002/rcm.8058.

15.

Evaluation of PrediXcan for prioritizing GWAS associations and predicting gene expression.

Li B, Verma SS, Veturi YC, Verma A, Bradford Y, Haas DW, Ritchie MD.

Pac Symp Biocomput. 2018;23:448-459.

16.

Race/ethnicity difference in the pharmacogenetics of bilirubin-related atazanavir discontinuation.

Leger P, Chirwa S, Nwogu JN, Turner M, Richardson DM, Baker P, Leonard M, Erdem H, Olson L, Haas DW.

Pharmacogenet Genomics. 2018 Jan;28(1):1-6. doi: 10.1097/FPC.0000000000000316.

17.

Genetics of human susceptibility to active and latent tuberculosis: present knowledge and future perspectives.

Abel L, Fellay J, Haas DW, Schurr E, Srikrishna G, Urbanowski M, Chaturvedi N, Srinivasan S, Johnson DH, Bishai WR.

Lancet Infect Dis. 2018 Mar;18(3):e64-e75. doi: 10.1016/S1473-3099(17)30623-0. Epub 2017 Oct 27. Review.

PMID:
29111156
18.

Evaluating the Impact of Functional Genetic Variation on HIV-1 Control.

McLaren PJ, Pulit SL, Gurdasani D, Bartha I, Shea PR, Pomilla C, Gupta N, Gkrania-Klotsas E, Young EH, Bannert N, Del Amo J, Gill MJ, Gilmour J, Kellam P, Kelleher AD, Sönnerborg A, Zangerle R, Post FA, Fisher M, Haas DW, Walker BD, Porter K, Goldstein DB, Sandhu MS, de Bakker PIW, Fellay J.

J Infect Dis. 2017 Nov 27;216(9):1063-1069. doi: 10.1093/infdis/jix470. Erratum in: J Infect Dis. 2018 Jun 5;218(1):171.

19.

Genetics of Nevirapine Metabolic Pathways at Steady State in HIV-Infected Cambodians.

Eloy P, Tessier A, Fan-Havard P, Chou M, Verstuyft C, Taburet AM, Haas DW, Bertrand J; ANRS12154 Study Group.

Antimicrob Agents Chemother. 2017 Nov 22;61(12). pii: e00733-17. doi: 10.1128/AAC.00733-17. Print 2017 Dec.

20.

Race/Ethnicity and the Pharmacogenetics of Reported Suicidality With Efavirenz Among Clinical Trials Participants.

Mollan KR, Tierney C, Hellwege JN, Eron JJ, Hudgens MG, Gulick RM, Haubrich R, Sax PE, Campbell TB, Daar ES, Robertson KR, Ventura D, Ma Q, Edwards DRV, Haas DW; AIDS Clinical Trials Group.

J Infect Dis. 2017 Sep 1;216(5):554-564. doi: 10.1093/infdis/jix248.

21.

Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.

Norwood J, Turner M, Bofill C, Rebeiro P, Shepherd B, Bebawy S, Hulgan T, Raffanti S, Haas DW, Sterling TR, Koethe JR.

J Acquir Immune Defic Syndr. 2017 Dec 15;76(5):527-531. doi: 10.1097/QAI.0000000000001525.

22.

Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles.

Pavlos R, McKinnon EJ, Ostrov DA, Peters B, Buus S, Koelle D, Chopra A, Schutte R, Rive C, Redwood A, Restrepo S, Bracey A, Kaever T, Myers P, Speers E, Malaker SA, Shabanowitz J, Jing Y, Gaudieri S, Hunt DF, Carrington M, Haas DW, Mallal S, Phillips EJ.

Sci Rep. 2017 Aug 17;7(1):8653. doi: 10.1038/s41598-017-08876-0.

23.

Multiphenotype association study of patients randomized to initiate antiretroviral regimens in AIDS Clinical Trials Group protocol A5202.

Verma A, Bradford Y, Verma SS, Pendergrass SA, Daar ES, Venuto C, Morse GD, Ritchie MD, Haas DW.

Pharmacogenet Genomics. 2017 Mar;27(3):101-111. doi: 10.1097/FPC.0000000000000263.

24.

Pharmacogenetics of efavirenz discontinuation for reported central nervous system symptoms appears to differ by race.

Leger P, Chirwa S, Turner M, Richardson DM, Baker P, Leonard M, Erdem H, Olson L, Haas DW.

Pharmacogenet Genomics. 2016 Oct;26(10):473-80. doi: 10.1097/FPC.0000000000000238.

25.

Patient willingness to undergo efavirenz dose reduction based on pharmacogenetic testing.

Mitchell M, Wells C, Zhang X, Hughes J, White J, Nash R, Haas DW.

Per Med. 2016 May;13(3):241-247. doi: 10.2217/pme-2015-0011. Epub 2016 Mar 22.

PMID:
29767607
26.

Host genetic predictors of the kynurenine pathway of tryptophan catabolism among treated HIV-infected Ugandans.

Lee SA, Mefford JA, Huang Y, Witte JS, Martin JN, Haas DW, Mclaren PJ, Mushiroda T, Kubo M, Byakwaga H, Hunt PW, Kroetz DL.

AIDS. 2016 Jul 17;30(11):1807-15. doi: 10.1097/QAD.0000000000001124.

27.

Pharmacogenetics of unboosted atazanavir in HIV-infected individuals in resource-limited settings: a sub-study of the AIDS Clinical Trials Group (ACTG) PEARLS study (NWCS 342).

Castillo-Mancilla JR, Aquilante CL, Wempe MF, Smeaton LM, Firnhaber C, LaRosa AM, Kumarasamy N, Andrade A, Baheti G, Fletcher CV, Campbell TB, Haas DW, MaWhinney S, Anderson PL.

J Antimicrob Chemother. 2016 Jun;71(6):1609-18. doi: 10.1093/jac/dkw005. Epub 2016 Feb 17.

28.

PHENOME-WIDE INTERACTION STUDY (PheWIS) IN AIDS CLINICAL TRIALS GROUP DATA (ACTG).

Verma SS, Frase AT, Verma A, Pendergrass SA, Mahony S, Haas DW, Ritchie MD.

Pac Symp Biocomput. 2016;21:57-68.

29.

Plasma Efavirenz Concentrations Are Associated With Lipid and Glucose Concentrations.

Sinxadi PZ, McIlleron HM, Dave JA, Smith PJ, Levitt NS, Haas DW, Maartens G.

Medicine (Baltimore). 2016 Jan;95(2):e2385. doi: 10.1097/MD.0000000000002385.

30.

Cost-effectiveness of CYP2B6 genotyping to optimize efavirenz dosing in HIV clinical practice.

Schackman BR, Haas DW, Park SS, Li XC, Freedberg KA.

Pharmacogenomics. 2015 Dec;16(18):2007-18. doi: 10.2217/pgs.15.142. Epub 2015 Nov 26.

31.

Polymorphisms of large effect explain the majority of the host genetic contribution to variation of HIV-1 virus load.

McLaren PJ, Coulonges C, Bartha I, Lenz TL, Deutsch AJ, Bashirova A, Buchbinder S, Carrington MN, Cossarizza A, Dalmau J, De Luca A, Goedert JJ, Gurdasani D, Haas DW, Herbeck JT, Johnson EO, Kirk GD, Lambotte O, Luo M, Mallal S, van Manen D, Martinez-Picado J, Meyer L, Miro JM, Mullins JI, Obel N, Poli G, Sandhu MS, Schuitemaker H, Shea PR, Theodorou I, Walker BD, Weintrob AC, Winkler CA, Wolinsky SM, Raychaudhuri S, Goldstein DB, Telenti A, de Bakker PI, Zagury JF, Fellay J.

Proc Natl Acad Sci U S A. 2015 Nov 24;112(47):14658-63. doi: 10.1073/pnas.1514867112. Epub 2015 Nov 9.

32.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing.

Gammal RS, Court MH, Haidar CE, Iwuchukwu OF, Gaur AH, Alvarellos M, Guillemette C, Lennox JL, Whirl-Carrillo M, Brummel SS, Ratain MJ, Klein TE, Schackman BR, Caudle KE, Haas DW; Clinical Pharmacogenetics Implementation Consortium.

Clin Pharmacol Ther. 2016 Apr;99(4):363-9. doi: 10.1002/cpt.269. Epub 2015 Nov 9. Review.

33.

Treatment Failure, Drug Resistance, and CD4 T-Cell Count Decline Among Postpartum Women on Antiretroviral Therapy in South Africa.

Hoffmann CJ, Cohn S, Mashabela F, Hoffmann JD, McIlleron H, Denti P, Haas DW, Dooley KE, Martinson NA, Chaisson RE.

J Acquir Immune Defic Syndr. 2016 Jan 1;71(1):31-7. doi: 10.1097/QAI.0000000000000811.

34.

Screening for UGT1A1 Genotype in Study A5257 Would Have Markedly Reduced Premature Discontinuation of Atazanavir for Hyperbilirubinemia.

Vardhanabhuti S, Ribaudo HJ, Landovitz RJ, Ofotokun I, Lennox JL, Currier JS, Olson LM, Haas DW.

Open Forum Infect Dis. 2015 Jul 1;2(3):ofv085. doi: 10.1093/ofid/ofv085. eCollection 2015 Sep.

35.

The diverse environmental burden of city-scale urban water systems.

Lane JL, de Haas DW, Lant PA.

Water Res. 2015 Sep 15;81:398-415. doi: 10.1016/j.watres.2015.03.005. Epub 2015 Mar 19.

PMID:
26164544
36.

Genomewide association study of tenofovir pharmacokinetics and creatinine clearance in AIDS Clinical Trials Group protocol A5202.

Wanga V, Venuto C, Morse GD, Acosta EP, Daar ES, Haas DW, Li C, Shepherd BE.

Pharmacogenet Genomics. 2015 Sep;25(9):450-61. doi: 10.1097/FPC.0000000000000156.

37.

Phenome-wide Association Study Relating Pretreatment Laboratory Parameters With Human Genetic Variants in AIDS Clinical Trials Group Protocols.

Moore CB, Verma A, Pendergrass S, Verma SS, Johnson DH, Daar ES, Gulick RM, Haubrich R, Robbins GK, Ritchie MD, Haas DW.

Open Forum Infect Dis. 2015 Jan 9;2(1):ofu113. doi: 10.1093/ofid/ofu113. eCollection 2015 Jan.

38.

Novel dosing strategies increase exposures of the potent antituberculosis drug rifapentine but are poorly tolerated in healthy volunteers.

Dooley KE, Savic RM, Park JG, Cramer Y, Hafner R, Hogg E, Janik J, Marzinke MA, Patterson K, Benson CA, Hovind L, Dorman SE, Haas DW; ACTG A5311 Study Team.

Antimicrob Agents Chemother. 2015;59(6):3399-405. doi: 10.1128/AAC.05128-14. Epub 2015 Mar 30.

39.

Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.

Luetkemeyer AF, Rosenkranz SL, Lu D, Grinsztejn B, Sanchez J, Ssemmanda M, Sanne I, McIlleron H, Havlir DV, Haas DW; Adult AIDS Clinical Trials Group A5221 and A5243 Study Teams.

Clin Infect Dis. 2015 Jun 15;60(12):1860-3. doi: 10.1093/cid/civ155. Epub 2015 Feb 26.

40.

Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.

Sinxadi PZ, Leger PD, McIlleron HM, Smith PJ, Dave JA, Levitt NS, Maartens G, Haas DW.

Br J Clin Pharmacol. 2015 Jul;80(1):146-56. doi: 10.1111/bcp.12590. Epub 2015 May 28.

41.

Perspectives on pharmacogenomics of antiretroviral medications and HIV-associated comorbidities.

Haas DW, Tarr PE.

Curr Opin HIV AIDS. 2015 Mar;10(2):116-22. doi: 10.1097/COH.0000000000000134. Review.

42.

Pharmacogenomics of antimicrobial agents.

Aung AK, Haas DW, Hulgan T, Phillips EJ.

Pharmacogenomics. 2014;15(15):1903-30. doi: 10.2217/pgs.14.147. Review.

43.

Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.

Lehmann DS, Ribaudo HJ, Daar ES, Gulick RM, Haubrich RH, Robbins GK, de Bakker PI, Haas DW, McLaren PJ.

Pharmacogenet Genomics. 2015 Feb;25(2):51-9. doi: 10.1097/FPC.0000000000000106.

44.

Summaries for patients. Nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1.

Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team.

Ann Intern Med. 2014 Oct 7;161(7):I-22. doi: 10.7326/P14-9035. No abstract available.

PMID:
25285557
45.

Efficacy and tolerability of 3 nonnucleoside reverse transcriptase inhibitor-sparing antiretroviral regimens for treatment-naive volunteers infected with HIV-1: a randomized, controlled equivalence trial.

Lennox JL, Landovitz RJ, Ribaudo HJ, Ofotokun I, Na LH, Godfrey C, Kuritzkes DR, Sagar M, Brown TT, Cohn SE, McComsey GA, Aweeka F, Fichtenbaum CJ, Presti RM, Koletar SL, Haas DW, Patterson KB, Benson CA, Baugh BP, Leavitt RY, Rooney JF, Seekins D, Currier JS; ACTG A5257 Team.

Ann Intern Med. 2014 Oct 7;161(7):461-71. doi: 10.7326/M14-1084. Erratum in: Ann Intern Med. 2014 Nov 4;161(9):680.

46.

Defining the role of common variation in the genomic and biological architecture of adult human height.

Wood AR, Esko T, Yang J, Vedantam S, Pers TH, Gustafsson S, Chu AY, Estrada K, Luan J, Kutalik Z, Amin N, Buchkovich ML, Croteau-Chonka DC, Day FR, Duan Y, Fall T, Fehrmann R, Ferreira T, Jackson AU, Karjalainen J, Lo KS, Locke AE, Mägi R, Mihailov E, Porcu E, Randall JC, Scherag A, Vinkhuyzen AA, Westra HJ, Winkler TW, Workalemahu T, Zhao JH, Absher D, Albrecht E, Anderson D, Baron J, Beekman M, Demirkan A, Ehret GB, Feenstra B, Feitosa MF, Fischer K, Fraser RM, Goel A, Gong J, Justice AE, Kanoni S, Kleber ME, Kristiansson K, Lim U, Lotay V, Lui JC, Mangino M, Mateo Leach I, Medina-Gomez C, Nalls MA, Nyholt DR, Palmer CD, Pasko D, Pechlivanis S, Prokopenko I, Ried JS, Ripke S, Shungin D, Stancáková A, Strawbridge RJ, Sung YJ, Tanaka T, Teumer A, Trompet S, van der Laan SW, van Setten J, Van Vliet-Ostaptchouk JV, Wang Z, Yengo L, Zhang W, Afzal U, Arnlöv J, Arscott GM, Bandinelli S, Barrett A, Bellis C, Bennett AJ, Berne C, Blüher M, Bolton JL, Böttcher Y, Boyd HA, Bruinenberg M, Buckley BM, Buyske S, Caspersen IH, Chines PS, Clarke R, Claudi-Boehm S, Cooper M, Daw EW, De Jong PA, Deelen J, Delgado G, Denny JC, Dhonukshe-Rutten R, Dimitriou M, Doney AS, Dörr M, Eklund N, Eury E, Folkersen L, Garcia ME, Geller F, Giedraitis V, Go AS, Grallert H, Grammer TB, Gräßler J, Grönberg H, de Groot LC, Groves CJ, Haessler J, Hall P, Haller T, Hallmans G, Hannemann A, Hartman CA, Hassinen M, Hayward C, Heard-Costa NL, Helmer Q, Hemani G, Henders AK, Hillege HL, Hlatky MA, Hoffmann W, Hoffmann P, Holmen O, Houwing-Duistermaat JJ, Illig T, Isaacs A, James AL, Jeff J, Johansen B, Johansson Å, Jolley J, Juliusdottir T, Junttila J, Kho AN, Kinnunen L, Klopp N, Kocher T, Kratzer W, Lichtner P, Lind L, Lindström J, Lobbens S, Lorentzon M, Lu Y, Lyssenko V, Magnusson PK, Mahajan A, Maillard M, McArdle WL, McKenzie CA, McLachlan S, McLaren PJ, Menni C, Merger S, Milani L, Moayyeri A, Monda KL, Morken MA, Müller G, Müller-Nurasyid M, Musk AW, Narisu N, Nauck M, Nolte IM, Nöthen MM, Oozageer L, Pilz S, Rayner NW, Renstrom F, Robertson NR, Rose LM, Roussel R, Sanna S, Scharnagl H, Scholtens S, Schumacher FR, Schunkert H, Scott RA, Sehmi J, Seufferlein T, Shi J, Silventoinen K, Smit JH, Smith AV, Smolonska J, Stanton AV, Stirrups K, Stott DJ, Stringham HM, Sundström J, Swertz MA, Syvänen AC, Tayo BO, Thorleifsson G, Tyrer JP, van Dijk S, van Schoor NM, van der Velde N, van Heemst D, van Oort FV, Vermeulen SH, Verweij N, Vonk JM, Waite LL, Waldenberger M, Wennauer R, Wilkens LR, Willenborg C, Wilsgaard T, Wojczynski MK, Wong A, Wright AF, Zhang Q, Arveiler D, Bakker SJ, Beilby J, Bergman RN, Bergmann S, Biffar R, Blangero J, Boomsma DI, Bornstein SR, Bovet P, Brambilla P, Brown MJ, Campbell H, Caulfield MJ, Chakravarti A, Collins R, Collins FS, Crawford DC, Cupples LA, Danesh J, de Faire U, den Ruijter HM, Erbel R, Erdmann J, Eriksson JG, Farrall M, Ferrannini E, Ferrières J, Ford I, Forouhi NG, Forrester T, Gansevoort RT, Gejman PV, Gieger C, Golay A, Gottesman O, Gudnason V, Gyllensten U, Haas DW, Hall AS, Harris TB, Hattersley AT, Heath AC, Hengstenberg C, Hicks AA, Hindorff LA, Hingorani AD, Hofman A, Hovingh GK, Humphries SE, Hunt SC, Hypponen E, Jacobs KB, Jarvelin MR, Jousilahti P, Jula AM, Kaprio J, Kastelein JJ, Kayser M, Kee F, Keinanen-Kiukaanniemi SM, Kiemeney LA, Kooner JS, Kooperberg C, Koskinen S, Kovacs P, Kraja AT, Kumari M, Kuusisto J, Lakka TA, Langenberg C, Le Marchand L, Lehtimäki T, Lupoli S, Madden PA, Männistö S, Manunta P, Marette A, Matise TC, McKnight B, Meitinger T, Moll FL, Montgomery GW, Morris AD, Morris AP, Murray JC, Nelis M, Ohlsson C, Oldehinkel AJ, Ong KK, Ouwehand WH, Pasterkamp G, Peters A, Pramstaller PP, Price JF, Qi L, Raitakari OT, Rankinen T, Rao DC, Rice TK, Ritchie M, Rudan I, Salomaa V, Samani NJ, Saramies J, Sarzynski MA, Schwarz PE, Sebert S, Sever P, Shuldiner AR, Sinisalo J, Steinthorsdottir V, Stolk RP, Tardif JC, Tönjes A, Tremblay A, Tremoli E, Virtamo J, Vohl MC; Electronic Medical Records and Genomics (eMEMERGEGE) Consortium; MIGen Consortium; PAGEGE Consortium; LifeLines Cohort Study, Amouyel P, Asselbergs FW, Assimes TL, Bochud M, Boehm BO, Boerwinkle E, Bottinger EP, Bouchard C, Cauchi S, Chambers JC, Chanock SJ, Cooper RS, de Bakker PI, Dedoussis G, Ferrucci L, Franks PW, Froguel P, Groop LC, Haiman CA, Hamsten A, Hayes MG, Hui J, Hunter DJ, Hveem K, Jukema JW, Kaplan RC, Kivimaki M, Kuh D, Laakso M, Liu Y, Martin NG, März W, Melbye M, Moebus S, Munroe PB, Njølstad I, Oostra BA, Palmer CN, Pedersen NL, Perola M, Pérusse L, Peters U, Powell JE, Power C, Quertermous T, Rauramaa R, Reinmaa E, Ridker PM, Rivadeneira F, Rotter JI, Saaristo TE, Saleheen D, Schlessinger D, Slagboom PE, Snieder H, Spector TD, Strauch K, Stumvoll M, Tuomilehto J, Uusitupa M, van der Harst P, Völzke H, Walker M, Wareham NJ, Watkins H, Wichmann HE, Wilson JF, Zanen P, Deloukas P, Heid IM, Lindgren CM, Mohlke KL, Speliotes EK, Thorsteinsdottir U, Barroso I, Fox CS, North KE, Strachan DP, Beckmann JS, Berndt SI, Boehnke M, Borecki IB, McCarthy MI, Metspalu A, Stefansson K, Uitterlinden AG, van Duijn CM, Franke L, Willer CJ, Price AL, Lettre G, Loos RJ, Weedon MN, Ingelsson E, O'Connell JR, Abecasis GR, Chasman DI, Goddard ME, Visscher PM, Hirschhorn JN, Frayling TM.

Nat Genet. 2014 Nov;46(11):1173-86. doi: 10.1038/ng.3097. Epub 2014 Oct 5.

47.

Pharmacokinetics of efavirenz and treatment of HIV-1 among pregnant women with and without tuberculosis coinfection.

Dooley KE, Denti P, Martinson N, Cohn S, Mashabela F, Hoffmann J, Haas DW, Hull J, Msandiwa R, Castel S, Wiesner L, Chaisson RE, McIlleron H; TSHEPISO Study Team.

J Infect Dis. 2015 Jan 15;211(2):197-205. doi: 10.1093/infdis/jiu429. Epub 2014 Jul 31. Erratum in: J Infect Dis. 2015 Jul 1;212(1):169.

48.

Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.

Dooley KE, Luetkemeyer AF, Park JG, Allen R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW; AIDS Clinical Trials Group A5306 Study Team.

Antimicrob Agents Chemother. 2014 Sep;58(9):5245-52. doi: 10.1128/AAC.03332-14. Epub 2014 Jun 23.

49.

A randomized controlled trial of palifermin (recombinant human keratinocyte growth factor) for the treatment of inadequate CD4+ T-lymphocyte recovery in patients with HIV-1 infection on antiretroviral therapy.

Jacobson JM, Wang H, Bordi R, Zheng L, Gross BH, Landay AL, Spritzler J, Routy JP, Benson C, Aberg J, Tebas P, Haas DW, Tiu J, Coughlin K, Purdue L, Sekaly RP; AIDS Clinical Trials Group (ACTG) A5212 Protocol Team.

J Acquir Immune Defic Syndr. 2014 Aug 1;66(4):399-406. doi: 10.1097/QAI.0000000000000195.

50.

Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.

Haas DW, Kwara A, Richardson DM, Baker P, Papageorgiou I, Acosta EP, Morse GD, Court MH.

J Antimicrob Chemother. 2014 Aug;69(8):2175-82. doi: 10.1093/jac/dku110. Epub 2014 Apr 11.

Supplemental Content

Support Center